Trial reportInternational urogynecology journal2026
Can Low Dose Tadalafil Improve the Sexual Functions in Women with Genital Mutilation?
Trial report in International urogynecology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction and hypothesisFemale genital mutilation (FGM) is associated with female sexual dysfunction (FSD) through anatomical disruption and impaired genital vascular function. Phosphodiesterase-5 inhibition may enhance genital perfusion via nitric oxide-mediated pathways. We hypothesized that tadalafil improves sexual function and clitoral vascular parameters in women with FGM-related FSD.
methodsIn this randomized, single-blind, placebo-controlled trial, 66 women with FGM-related FSD were randomized; 52 completed follow-up and were included in a modified intention-to-treat analysis (tadalafil 5 mg once daily, n = 25; placebo, n = 27) for 8 weeks. Sexual function was assessed using the Female Sexual Function Index (FSFI). Their FGM type was classified on the basis of WHO criteria. Clitoral color Doppler ultrasonography measured peak systolic velocity (PSV), resistance index (RI), and pulsatility index (PI). The primary endpoint was the between-group difference in change in total FSFI score from baseline to 8 weeks.
resultsBaseline characteristics were comparable between groups. Tadalafil significantly improved total FSFI score compared with placebo (mean change +5.47 vs -0.41; p < 0.001). Improvements were observed across all FSFI domains except lubrication. Significant increases in clitoral PSV, RI, and PI were detected in the tadalafil group, whereas no significant changes occurred in the placebo group. Greater benefit was observed in women with type I FGM.
conclusionsOnce-daily tadalafil 5 mg for 8 weeks significantly improves sexual function and genital vascular parameters in women with FGM-related FSD, supporting its potential therapeutic role in this population.
Indexed as
Identifiers
42010170What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.